TRICCAR Holdings, Inc. announces retention of Young America Capital to lead $12 million Series B
LAS VEGAS - Jan. 31, 2019 - PRLog -- TRICCAR Holdings, Inc., aka, TRICCAR, today announced it has retained the services of New York-based investment bank Young America Capital to lead its Series B financing in what is expected to be its final financing round before going public.
"Young America Capital has shown incredible flexibility and ingenuity in raising capital for companies in industries related to our fully integrated bioceutical business model. We are excited to be working with the firm in an official investment banker relationship,"
Jon Lunsford, Managing Director at Young America Capital, is leading the $12,000,000 Series B raise for TRICCAR, the proceeds of which will be used to bring 13 products to market in the 24 months post-close.
"TRICCAR is one of the most exciting bioceutical companies to come along that combines bioceutical and pharmaceutical investigations with significantly higher than industry average success rates," said Lunsford. "The Company's outstanding management and medical team have created a pipeline of products that have been in development since 2014, double blind tested, and are now ready for consumer use. Largely by virtue of its founder and core team, it has been able to attract seasoned researchers from leading medical centers, universities and companies like Procter & Gamble."
TRICCAR was formed in 2014 when Townsend's sister-in-law was diagnosed with amyotrophic lateral sclerosis (ALS or Lou Gehrig's Disease). Exhausting all western and eastern pharmaceutical treatments, Townsend began investigating natural formulae to reduce her pain and suffering, resulting in a bioceutical supplement which has increased her nightly sleep from an average of 1 hour to 6-8 hours and decreased her pain levels from 8-9 to 0-1.
TRICCAR has invested approximately $7 million in clinical research and development, raising $5 million through a Series A with a valuation of $50 million. Since then it has acquired patented formulae backed by over $60 million in clinical research. The company expects 2019 revenue to exceed $16 million.
TRICCAR is a Las Vegas, Nevada-based bioceutical company creating treatments that support the health of those suffering from the world's most common diseases, including, obesity, cancer, pain, diabetic neuropathy, calcium deficiency, and trigeminal neuralgia. The Company competes in markets estimated at $1 trillion in annual sales for human and animal care.
Young America Capital is a SEC registered, FINRA regulated broker dealer based in Mamaroneck, New York.
For additional information, visit TRICCAR at http://www.triccar.com